Institute for Regenerative Medicine, Medical Innovation Center and State Key Laboratory of Cardiology, Shanghai East Hospital, School of Life Sciences and Technology, Tongji University, Shanghai, China.
Institute of Cellular Drug Development, Shanghai iCELL Biotechnology Co., Ltd, Shanghai, China.
Front Immunol. 2024 Oct 15;15:1466529. doi: 10.3389/fimmu.2024.1466529. eCollection 2024.
Human amniotic epithelial cells (hAECs) have shown promising therapeutic effects in numerous studies on various diseases due to their properties such as low immunogenicity, immunomodulation, paracrine effect, and no teratoma formation . Nevertheless, there are still many problems in archiving the large-scale clinical application of hAECs, ranging from the vague definition of cell properties to the lack of clarification of the motion of actions in cell therapies, additionally, to the gap between cell quantities with limited proliferation capacity. This review provides a detailed overview of hAECs in the aspects of the lineage development of amniotic epithelial cell, cell characteristics and functional roles, cell cultivation and expansion systems, as well as their current status and limitations in clinical applications. This review also discusses the advantages, limitations and feasibility of hAECs, and anticipates their prospects as cell therapy products, with the aim of further promoting their clinical applications.
人羊膜上皮细胞（hAECs）由于其低免疫原性、免疫调节、旁分泌作用和无畸胎瘤形成等特性，在多种疾病的研究中显示出有希望的治疗效果。然而，在 hAECs 的大规模临床应用中仍存在许多问题，从细胞特性的模糊定义到细胞治疗中作用机制的不明确，再到有限增殖能力的细胞数量差距。本综述从羊膜上皮细胞系发育、细胞特性和功能作用、细胞培养和扩增系统等方面详细概述了 hAECs，以及它们在临床应用中的现状和局限性。本综述还讨论了 hAECs 的优势、局限性和可行性，并预测了它们作为细胞治疗产品的前景，以期进一步促进其临床应用。
